REPCF (0913693 BC) Net Income From Continuing Operations: $-0.06 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Net Income From Continuing Operations?

0913693 BC REPCF Net Income From Continuing Operations is $-0.06 Mil as of Sep. 2023.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. 0913693 BC's net income from continuing operations for the three months ended in Sep. 2023 was $-0.61 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.06 Mil.

0913693 BC Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Net Income From Continuing Operations Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.07 -2.28 -1.23 -3.18 -0.55

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 1.67 -0.70 -0.42 -0.61

0913693 BC Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-0.06 Mil mean?
0913693 BC (REPCF) has a Net Income From Continuing Operations of $-0.06 Mil as of Sep. 2023. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for 0913693 BC and its competitors.
Is 0913693 BC's Net Income From Continuing Operations too high?
0913693 BC's current Net Income From Continuing Operations is $-0.06 Mil.
How does 0913693 BC's Net Income From Continuing Operations compare to VRTX and REGN?
0913693 BC's Net Income From Continuing Operations of $-0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for 0913693 BC and its competitors. 0913693 BC's current Net Income From Continuing Operations is $-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 0913693 BC stock overvalued right now?
0913693 BC (REPCF) has a current Net Income From Continuing Operations of $-0.06 Mil. The current Net Income From Continuing Operations is $-0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For 0913693 BC (REPCF), the current Net Income From Continuing Operations is $-0.06 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.